CD106 (VCAM-1) Monoclonal Antibody (eBioMR106 (MR106)), eBioscience™, Invitrogen™

Description

Description: The eBioMR106 monoclonal antibody reacts with rat CD106 (Vascular Cell Adhesion Molecule-1, VCAM-1), a 110 kDa transmembrane glycoprotein expressed by myeloid lineage and bone marrow stromal cells. Endothelial cells constitutively express low levels of CD106 and further upregulate VCAM-1 upon cytokine stimulation. CD106 binds to integrin alpha4beta1 (VLA-4, CD49d/CD29) and Integrin alpha4beta7 (LPAM-1) and these interactions in the bone marrow and thymus are important for early lymphocyte and myeloid development. Cytokine-mediated upregulation of CD106 on endothelial cells suggests a role for this antigen in the inflammatory response. Applications Reported: This eBioMR106 (MR106) antibody has been reported for use in flow cytometric analysis, immunoprecipitation, immunoblotting (WB), and immunohistology staining of frozen tissue sections. Applications Tested: This eBioMR106 (MR106) antibody has been tested by flow cytometric analysis of rat bone marrow cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE.

VCAM-1 is a cell surface sialoglycoprotein expressed by cytokine activated endothelium. The protein has a number of functions including the regulation of leukocyte migration, leukocyte-endothelial cell adhesion and signal transduction and may play a role in a number of inflammatory diseases.